Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer

Date 22 October 2018
Event ESMO 2018 Congress
Session Proffered paper session - NETs and endocrine tumours
Topics Thyroid Cancer
Anticancer Agents
Presenter Sophie Leboulleux
Citation Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302
Authors S. Leboulleux1, E.K. Lee2, L. Bastholt3, M. Tahara4, L.J. Wirth5, S.I. Sherman6, B.G. Robinson7, A. Teng8, P. Joshi8, S. Misir8, C.E. Dutcus8, R.M. Tuttle9, M.J. Schlumberger1
  • 1Gustave Roussy, University Paris-Saclay, 94805 - Villejuif/FR
  • 2Center For Thyroid Cancer, National Cancer Center, Goyang-si/KR
  • 3Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 4Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 5Cancer Center, Massachusetts General Hospital, Boston/US
  • 6Endocrine Neoplasia And Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston/US
  • 7Kolling Institute Of Medical Research, The University of Sydney, New South Wales/AU
  • 8Oncology Business Unit, Eisai Inc., 07677 - Woodcliff Lake/US
  • 9Endocrinology, Memorial Sloan-Kettering Cancer Center, New York/US



Patients (pts) with differentiated thyroid cancer (DTC) are a heterogeneous group. Tumor growth rate (TGR) is correlated with life expectancy. Lenvatinib (LEN) is approved for radioiodine-refractory DTC based on the phase 3 SELECT trial. Here we examine TGR and efficacy outcomes from SELECT.


Per SELECT eligibility criteria, pts had independent radiologic evidence of progression within 13 months prior to randomization (prebaseline) to LEN or placebo (PBO). In this post hoc, exploratory analysis, pre-randomization TGR was assessed per pt as: (sum of target lesions at baseline – sum of target lesions at prebaseline) divided by sum of target lesions at prebaseline, and then divided by the interval of time between the 2 examinations (in mos). Pts were dichotomized: slow TGR (TGR ≤ median TGR of all SELECT pts) vs fast TGR (TGR > median). Subgroups were: baseline liver metastases (yes vs no), age (≤65 vs > 65 y), histology (papillary vs follicular), ECOG PS (0 vs ≥ 1), and baseline thyroid-stimulating hormone (TSH) (≤0.1 vs > 0.1 uIU/mL).


In a multivariate model, TGR of pts on LEN was significantly associated with baseline tumor size, and baseline liver, bone, and other metastases. When comparing treatment arms, LEN improved progression-free survival (PFS) vs PBO in both slow TGR (median 20.2 vs 3.7 mos; HR 0.19; 95% CI 0.12–0.32; P < 0.001) and fast TGR groups (median 14.8 vs 3.5 mos; HR 0.20; 95% CI 0.12–0.33; P < 0.001). PFS of LEN-treated pts was significantly longer in the slow vs fast TGR group (median 20.2 vs 14.8 mos; HR 0.62; 95% CI 0.41–0.94; P = 0.0232). Differences were also seen for PFS between slow and fast TGR groups in pts >65 years, pts with ECOG PS 0, and pts with baseline TSH >0.1 uIU/mL. When comparing treatment arms, overall survival (OS) trends favored LEN over PBO in both slow (medians not reached [NR]; HR 0.53; 95% CI 0.29–0.97) and fast TGR groups (LEN, NR vs PBO, 20.3 mos; HR 0.78; 95% CI 0.43–1.39); however, significance was not achieved in the fast TGR group. Among pts on LEN, OS was similar between slow and fast TGR groups (HR 0.77; 95% CI 0.46–1.29); no trends were seen in subgroup analyses.


In SELECT, LEN conferred benefit over PBO for all pts regardless of TGR; however, PFS was significantly longer in pts with slower TGR.

Clinical trial identification


Legal entity responsible for the study

Eisai Inc.


Eisai Inc.

Editorial Acknowledgement

Editorial support was provided by Oxford PharmaGenesis of Newtown, PA, USA, and was sponsored by Eisai Inc.


S. Leboulleux: Honoraria: Sanofi Genzyme, Bayer; Consulting/advisory role: Sanofi Genzyme; Research funding (institutional support): Bayer, Novartis; Travel/accommodations/expenses: Sanofi Genzyme. E.K. Lee: Consulting/advisory role: Eisai. L. Bastholt: Consulting/advisory role: Merck, BMS, Roche, Eisai, Incyte, Novartis; Travel/accommodations expenses: Merck, BMS, Novartis. M. Tahara: Honoraria: Bayer, Bristol-Myers Squibb, Eisai, Merck Serono, Takeda; Consulting/ advisory role: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Ono Pharmaceutical, Pfizer; Research funding (institutional support): AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Merck Sharp & Dohme, NanoCarrier, Novartis, Ono Pharmaceutical, Pfizer. L.J. Wirth: Consulting/advisory role: Amgen, Blueprint Medicines, Eisai, Loxo, Merck; Research funding: AstraZeneca, Bayer, Eisai. S.I. Sherman: Grant: Eisai, Pfizer, Genzyme; Personal fees: Eisai, Exelixis, Bayer, Onyx, AstraZeneca, Veracyte, NovoNordisk, Eli Lilly, Genzyme, Roche. B.G. Robinson: Personal fees: Eisai, AstraZeneca, Bayer. A. Teng, P. Joshi, S. Misir, C.E. Dutcus: Employee: Eisai Inc. R.M. Tuttle: Honoraria: Bayer, Eisai, Genzyme, Novo Nordisk; Consulting/advisory role: Eisai, Novo Nordisk; Research funding: AstraZeneca; Travel, accommodations, expenses: Bayer, Eisai, Genzyme, Novo Nordisk. M.J. Schlumberger: Consulting/advisory role: Bayer, Eisai, Ipsen, Sanofi Genzyme; Research funding: Eisai.